The upcoming AdCom in late July and PDUFA date on August 2 are the primary catalysts. Approval of RP1 would mark Replimune's first commercial product. Monitor for any FDA briefing documents or panel recommendations ahead of the AdCom.
REPL drugs
REPL drug pipeline →Price Chart
Executive Summary
Replimune reported fiscal Q4 2026 results with net loss of $73.7M, in line with expectations for a pre-revenue biotech. The key catalyst is the FDA's acceptance of the RP1 BLA resubmission with a PDUFA goal date of August 2, 2026, and an advisory committee meeting scheduled for late July. Cash of $268.9M supports operations into early calendar 2027.
Key Facts
- FDA accepted RP1 BLA resubmission as a complete, class 1 response with PDUFA date August 2, 2026.
- Advisory committee meeting expected in late July 2026.
- Cash, cash equivalents and short-term investments were $268.9M as of March 31, 2026.
- Net loss for Q4 fiscal 2026 was $73.7M, full year net loss $313.9M.
- Cash runway extends into early calendar 2027, excluding potential revenue.
Financial Impact
No revenue; net loss increased to $73.7M for the quarter (from $74.1M a year ago). Cash burn rate consistent with R&D and pre-commercial scale-up.
Risk Factors
- FDA may not approve RP1, or may require additional data.
- Competition from other oncolytic virus therapies and checkpoint inhibitors.
- Cash runway limited; may need financing before revenue materializes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-078511 |
| Document: tm2619129d1_8k.htm | 0001104659-26-078511 |
| Document: 0001104659-26-078511-index-headers.html | 0001104659-26-078511 |
| Document: 0001104659-26-078511-index.html | 0001104659-26-078511 |
| Document: 0001104659-26-078511.txt | 0001104659-26-078511 |
| 8-K Data (Synthetic) | 0001104659-26-078511 |
Track record
32 reports on REPL
9 of 13 bullish or bearish reports moved the stock their way by T+60. Best: +188.35% at T+20 after the Jul 30, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $21.90 Now $21.41 −2.24% settles Feb 12
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $21.78 Now $21.41 −1.70% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $23.28 Now $21.41 −8.03% settles Feb 8
- Nov 9, 20267d ago SC 13G/A Neutral 2/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 6, 202610d ago 10-Q/A Neutral 3/10 Entry $22.26 Now $21.41 −3.82% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Bearish 4/10 Entry $20.69 Now $21.41 −3.48% settles Feb 2
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $20.69 Now $21.41 +3.48% settles Feb 2
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $20.65 Now $21.41 +3.68% settles Feb 1
- Oct 30, 202617d ago 144 Neutral 2/10 Entry $19.49 Now $21.41 +9.85% settles Jan 29
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers